Xeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q1 EPS of ($0.30), $0.04 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $8.1 million versus the consensus estimate of $7.47 million.

“We are very pleased with our steady, consistently growing financial performance in the first quarter notwithstanding the continued challenges created by the global pandemic. Demand for Gvoke grew despite a suppressed market, Ogluo received approval in the EU and UK, and our discussions with the FDA have provided clarity for our proposed Phase 3 study designs,” said Paul R. Edick, Chairman and CEO of Xeris. “Our momentum is continuing into the second quarter, and we are encouraged by what appears to be more stability in the overall endocrinology market and the glucagon market specifically.”

For earnings history and earnings-related data on Xeris Pharmaceuticals Inc. (XERS) click here.